Antidepressants: Past, Present and Future: Past, Present, and FutureThis book is being published as we mark the end of the first 50 years of the modern antidepressant era. This era began with the chance discovery that tri- clic antidepressants and monoamine oxidase inhibitors had antidepressant p- perties. That discovery had three consequences. First, it brought simple and effective treatment to patients suffering from major depressive illnesses. Second, these discoveries, together with the discovery of lithium and chlorpromazine, began the remedicalization of psychiatry by making it clear that the treatment of many of the major psychiatric illnesses can be approached in the same way as other medical conditions. However, the most far-reaching effect was to provide the first clue as to what mechanisms might underlie antidepressant efficacy, a development that has led to an explosion in the number of available an- depressants and to their widespread use. The goal of this book is to provide a thorough review of the current status of antidepressants—how we arrived at this point in their evolution and where we are going in both the near and the long term. The book employs both a scientific and historical approach to accomplish these goals. The book is intended for practitioners who use antidepressants on a daily basis in their practice as well as for the student and researcher. Each will find that the book provides a comprehensive and logical approach to this important group of medications. The importance of the book is a function of its topic. |
Other editions - View all
Antidepressants: Past, Present and Future Sheldon H. Preskorn,Christina Y. Stanga,John P. Feighner,Ruth Ross No preview available - 2012 |
Antidepressants: Past, Present and Future Sheldon H Preskorn,Christina Y Stanga,John P Feighner No preview available - 2004 |
Common terms and phrases
activity adverse effects affective disorders agents amine amitriptyline antide antidepres antidepressant drugs anxiety Arch Gen Psychiatry binding bipolar disorder brain bupropion chronic citalopram Clin Pharmacol Clin Psychiatry Clin Psychopharmacol clinicians clomipramine CYP 2D6 CYP enzymes decreased depres depressed patients desipramine dopamine dose double-blind drug concentration duloxetine efficacy elderly factors Feighner fluoxetine fluvoxamine function G protein half-life HAM-D hormone hypericum imipramine increase inhibition Janicak lithium major depressive disorder MAOIS mechanism of action medication metabolism metabolites mg/day milnacipran mirtazapine moclobemide monoamine oxidase nefazodone neurons neurotransmitter norepinephrine paroxetine personality disorder pharmacokinetics pharmacological phenelzine placebo placebo-controlled plasma concentrations plasma levels platelet potential Preskorn SH pressant protein kinase Psychiatry Psychopharmacology reboxetine receptors reported response role selective serotonin reuptake serotonergic serotonin reuptake inhibitors sertraline side effects SSRIs studies symptoms TCAs therapeutic drug monitoring therapy tianeptine tients tion toxicity trazodone treat treatment of depression tricyclic antidepressants uptake pump venlafaxine
Popular passages
Page 548 - Charney DS (1997). Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154: 624-629.